@bernardkadosh.bsky.social
Heart Failure and Transplant Cardiologist @NYU | Director, Cardiogenic Shock and VAD Program | APD, AHFTC Fellowship | Opinions are mine and not advice. Ready, able, and hemodynamically stable.
💯
Just because you can, doesn’t mean you should
Check out our editorial wherein my colleague Arushi Singh and I opine on the impact of obesity on heart #transplant outcomes. All hail #dadjokes as effective forms of communication.
Article by D Kim and J Kobashigawa:
doi.org/10.1016/j.he...
Our Editorial:
www.jhltonline.org/article/S105...
#ISHLT President Elect Josef Stehlik joins us at NYU for a perspective on🫀 #transplant
Register now! bit.ly/NYUAHF2025
#MedEd #CardioEd #CardioSky #Cardiology #HeartFailure #ISHLT2025
🫀AHFTC and CCC folks come spend a weekend in NYC with some of the nation's best talking shop about all things #CardiogenicShock #Transplant #LVAD #TAH and more!
ONE month away⌚️
Register now: bit.ly/NYUAHF25
#ACC25 #ISHLT2025 #Cardiology #CardioSky
High winds and truth bombs 💣 in Chicago at #ACC25
☝️There is nothing “routine”about #CardiogenicShock
✌️Hemodynamics are the closest thing we have to truth in this world
👊Rules are made to be broken. Embrace complexity!
@allisondupont.bsky.social
@sarasvallabhmd.bsky.social
MCS: Which Device For Which Patient?
Join me and an esteemed panel as we address some of your most 🔥 burning questions 🔥 and I share my philosophy on treating #CardiogenicShock 🧐 🤔 🤨
@allisondupont.bsky.social #ACC25 #cardiosky
📢Check out this issue of #JHLT wherein the crackerjack team At NYU highlights a gap in the current 🫀 allocation system. Anyone who has cared for a young patient with CAV knows this pain.
t.co/Slbb4jLT6h
We are and already do. This trial created a permission structure to do the easiest thing for patients in complex situations. Not saying it’s always wrong, but binary decision making in shock leads to many unintended consequences. This is why we use shock teams to think of all possible futures.
Ask me about the time we found a part of one sticking through the right ventricle 🏹
Now this is a curve that says, “seemed like a good idea at the time…”
#CardioSky #MedSky
😂
Very proud of our team @nyulangonepccsm.bsky.social
Making science fiction a new reality for patients with no other options.
#Transplant #HealthEquity
👀 #CAV patients listed for #HeartTransplant face higher mortality than others at the same status.
Status 4 = Status 3
Status 3 = Status 2
Guess we need to get our #OPTN priorities straight 🥁
www.sciencedirect.com/science/arti...
#CardioSky #MedSky #TransplantEquity #HealthEquity
Would definitely be helpful!
Totally agree. The obsession over EF has hamstrung research efforts and clinical progress.
Amen
Otherwise other afterload reducers would be just as effective in HFrEF and that is just not the case (prazosin, amlodipine, metoprolol tartrate)
Agree, but more than that, EF is an artifact of LV dilatation; a function of a specific type of cardiomyopathy. GDMT works independently of afterload reduction by reducing beta receptor downregulation and preventing neurohormonal pathways to fibrosis.
HFpEF pathology is completely different
So you’re selecting a treatment group that can tolerate SGLT2i that had a high rate of discontinuation for hypotension in the trials.
Skeptical of these results for a few reasons. The HFpEF trials of late benefit from enrollment of EF down to 40% which we know includes a HFrEF phenotype that responds to GDMT.
Propensity matching in this group is frought. Sick amyloids can barely tolerate any meds due to dysautonomia.
Quick comment on my end. The app is great, but reporting the % size is problematic.
We insist that the PHM RATIO is reported to avoid communication errors between team members with a misplaced or missing minus sign.
Mechanical Circulatory Support for Acute MI Cardiogenic Shock:
Review & Recent Updates
#CardioSky #MedSky
www.jcvaonline.com/article/S105...
I don’t yet have an avenue to help but I’ll be happy to speak with them if they need advice
Not the best level of evidence but this is consistent with my clinic experience using Entresto in ESRD patients. Have managed to get some recovered EFs to kidney transplant alone!
www.ahajournals.org/doi/10.1161/...
So proud of mentee Dr. Sidhu who just matched at NYU for cardiology fellowship. Her future is bright - and we are lucky to have her. #CardioSky #Match2024
Really excellent state of the art review on the topic of withdrawal of GDMT
www.jacc.org/doi/10.1016/...
#cardiosky #medsky
The patients you run into trouble with are usually diabetics with RTA. Sometimes the chronic CKD patients do this too, but I’m comfortable starting GDMT even with GFR in the 20-30 range. The renal function can improve over time, especially if you pay attention to volume status.
My threshold is much higher. I don’t discontinue unless the K is over 5.8 or so. Much of the time the patient just needs to hydrate a little and repeat the labs.